Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer

Autor: Michael J. Guarino, Kathir Suppiah, David D. Biggs, Charles J. Schneider, Jamal Misleh, Nicole F. Laslett, Gregory A. Masters, Pamela S. Simpson, Stephen S. Grubbs, Timothy F. Wozniak, SuJung Park

Publikováno v: Cancer Medicine, Vol 7, Iss 7, Pp 2969-2973 (2018)
Cancer Medicine

Lung cancer remains the leading cause of cancer death throughout the world. Despite new chemotherapeutic, immunomodulating and molecularly targeted agents, patients with locally advanced or metastatic disease still have a poor prognosis. This trial l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083ba8baff424584ce29e66305a41cb7
https://doi.org/10.1002/cam4.1569

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study

Autor: Emerson A. Lim, Daniel P. Petrylak, Kevin Kalinsky, Matthew D. Galsky, Pamela S. Simpson, Elaine T. Lam, William A. Wegener, Scott T. Tagawa, Bishoy Faltas, Julio Hajdenberg, Philip J. Saylor, Aditya Bardia, Alicia K. Morgans, Trishna Goswam

Publikováno v: Journal of Clinical Oncology. 37:354-354

354 Background: Patients (pts) with mUC who progress after platinum (PLT)-based chemotherapy and immune checkpoint inhibitor (CPI) therapy have poor outcomes and limited treatment options. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72583e97334b0f351fdec241ea5e4be1
https://doi.org/10.1200/jco.2019.37.7_suppl.354

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Autor: Dotan E; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Cohen SJ; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Starodub AN; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Lieu CH; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Messersmith WA; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Simpson PS; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Guarino MJ; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Marshall JL; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Goldberg RM; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Hecht JR; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Wegener WA; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Sharkey RM; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Govindan SV; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Goldenberg DM; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN., Berlin JD; Efrat Dotan and Steven J. Cohen, Fox Chase Cancer Center, Philadelphia, PA; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Christopher H. Lieu and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Pamela S. Simpson and Michael J. Guarino, Helen F. Graham Cancer Center & Research Institute, Newark, DE; John L. Marshall, Ruesch Center for the Cure of GI Cancers, Georgetown University Hospital, Washington, DC; Richard M. Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH; J. Randolph Hecht, University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ; and Jordan D. Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Oct 10; Vol. 35 (29), pp. 3338-3346. Date of Electronic Publication: 2017 Aug 17.